Skip to main content

Advertisement

SpringerLink
Log in

Getting the right drug into the right patient

  • Feature
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

Pharmacogenomics will help explain why drugs work better in some patients than in others. These tools should be used as early in the drug development process as possible.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Pharmaceutical Researchers and Manufacturers of America.

  2. Poirer,J. et al. 1995. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer's disease. Proc. Natl. Acad. Sci. USA 92: 12260–12264.

    Article  Google Scholar 

  3. Farlow, M.R. et al. 1996. Apolipoprotein E genotype and gender influence response to tacrine therapy. Ann. NY Acad. Sci. 802: 101–110.

    Article  CAS  Google Scholar 

  4. Richard, F. et al. 1997. APOE genotyping and response to drug treatment in Alzheimer's disease. Lancet 349: 539.

    Article  CAS  Google Scholar 

  5. Department of Health and Human Services. 1997. Guidance for Industry: Drug Metabolism/Drug Interaction Studies in the Drug Development Process: Studies in Vitro. FDA, Rockville, MD.

Download references

Authors
  1. Andrew Marshall
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marshall, A. Getting the right drug into the right patient. Nat Biotechnol 15, 1249–1252 (1997). https://doi.org/10.1038/nbt1197-1249

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt1197-1249

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation